Home LiteratureArticle Details
PMID: 9847337 Published · ppublish English Journal Article

Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells.

Journal of virology ·Vol. 73 ·No. 1 ·1999-01-00 ·Pages 334-42

Redchenko IV, Rickinson AB

Abstract

The conventional means of studying Epstein-Barr virus (EBV)-induced cytotoxic T-lymphocyte (CTL) memory, by in vitro stimulation with the latently infected autologous lymphoblastoid cell line (LCL), has important limitations. First, it gives no information on memory to lytic cycle antigens; second, it preferentially amplifies the dominant components of latent antigen-specific memory at the expense of key subdominant reactivities. Here we describe an alternative approach, based on in vitro stimulation with epitope peptide-loaded dendritic cells (DCs), which allows one to probe the CTL repertoire for any individual reactivity of choice; this method proved significantly more efficient than stimulation with peptide alone. Using this approach we first show that reactivities to the immunodominant and subdominant lytic cycle epitopes identified by T cells during primary EBV infection are regularly detectable in the CTL memory of virus carriers; this implies that in such carriers chronic virus replication remains under direct T-cell control. We further show that subdominant latent cycle reactivities to epitopes in the latent membrane protein LMP2, though rarely undetectable in LCL-stimulated populations, can be reactivated by DC stimulation and selectively expanded as polyclonal CTL lines; the adoptive transfer of such preparations may be of value in targeting certain EBV-positive malignancies.

MeSH Terms
DNA-Binding Proteins/immunology Dendritic Cells/physiology Epstein-Barr Virus Nuclear Antigens/immunology Herpesvirus 4, Human/immunology Humans Immunodominant Epitopes Immunologic Memory T-Lymphocytes, Cytotoxic/immunology Trans-Activators/immunology Viral Matrix Proteins/immunology Viral Proteins
Chemicals
BZLF1 protein, Herpesvirus 4, Human DNA-Binding Proteins EBV-associated membrane antigen, Epstein-Barr virus Epstein-Barr Virus Nuclear Antigens Immunodominant Epitopes Trans-Activators Viral Matrix Proteins Viral Proteins
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Redchenko I V
CRC Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham, B15 2TA United Kingdom.
Rickinson A B
References (58)
58 references, click to expand
  1. Expression of Epstein-Barr virus-encoded growth-transformation-associated proteins in lymphoproliferations of bone-marrow transplant recipients.
    Int J Cancer. 1991 Jan 21;47(2):188-92 PMID: 1846349
  2. In vitro human cytotoxic T cell responses against influenza A virus can be induced and selected by synthetic peptides.
    Eur J Immunol. 1990 Oct;20(10):2171-6 PMID: 2242754
  3. Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells.
    Immunology. 1991 Nov;74(3):399-406 PMID: 1769689
  4. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
    J Exp Med. 1992 Jul 1;176(1):157-68 PMID: 1319456
  5. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
    J Exp Med. 1992 Jul 1;176(1):169-76 PMID: 1377222
  6. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily.
    J Immunol. 1992 Jul 15;149(2):735-42 PMID: 1378080
  7. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells.
    Nature. 1992 Nov 19;360(6401):258-61 PMID: 1279441
  8. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo.
    J Exp Med. 1993 Aug 1;178(2):479-88 PMID: 7688024
  9. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.
    J Exp Med. 1993 Sep 1;178(3):879-87 PMID: 7688791
  10. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.
    J Exp Med. 1994 Apr 1;179(4):1109-18 PMID: 8145033
  11. T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues.
    J Exp Med. 1994 Apr 1;179(4):1297-305 PMID: 7511684
  12. Proliferating dendritic cell progenitors in human blood.
    J Exp Med. 1994 Jul 1;180(1):83-93 PMID: 8006603
  13. Generation of antigen-specific CD8+ CTLs from naive precursors.
    J Immunol. 1994 Aug 1;153(3):996-1003 PMID: 8027569
  14. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases.
    J Exp Med. 1997 Oct 20;186(8):1213-21 PMID: 9334360
  15. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines.
    Blood. 1997 Aug 15;90(4):1594-9 PMID: 9269778
  16. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
    Lancet. 1995 Jan 7;345(8941):9-13 PMID: 7799740
  17. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity.
    J Exp Med. 1997 Oct 20;186(8):1247-56 PMID: 9334364
  18. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.
    Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12616-21 PMID: 9356498
  19. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo.
    Eur J Immunol. 1997 Oct;27(10):2702-7 PMID: 9368629
  20. Dendritic cells as adjuvants for immune-mediated resistance to tumors.
    J Exp Med. 1997 Oct 20;186(8):1183-7 PMID: 9379142
  21. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing.
    Immunity. 1997 Dec;7(6):791-802 PMID: 9430224
  22. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
    Nat Med. 1998 Mar;4(3):328-32 PMID: 9500607
  23. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs.
    Nature. 1998 Mar 5;392(6671):86-9 PMID: 9510252
  24. Dendritic cells and the control of immunity.
    Nature. 1998 Mar 19;392(6673):245-52 PMID: 9521319
  25. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
    Eur J Immunol. 1994 Dec;24(12):3038-43 PMID: 7805731
  26. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01-positive African population.
    Eur J Immunol. 1995 Jan;25(1):102-10 PMID: 7531142
  27. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    J Immunol. 1995 Mar 1;154(5):2257-65 PMID: 7868898
  28. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells.
    J Immunol. 1995 Apr 15;154(8):3991-8 PMID: 7706738
  29. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.
    Nature. 1995 Jun 22;375(6533):685-8 PMID: 7540727
  30. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus.
    J Virol. 1995 Aug;69(8):4872-9 PMID: 7609055
  31. Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood.
    Eur J Immunol. 1995 Jun;25(6):1783-7 PMID: 7615008
  32. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro.
    Cancer Res. 1995 Nov 15;55(22):5330-4 PMID: 7585596
  33. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity.
    Nat Med. 1995 Dec;1(12):1297-302 PMID: 7489412
  34. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen.
    J Exp Med. 1995 Dec 1;182(6):1703-15 PMID: 7500015
  35. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.
    J Exp Med. 1996 Jan 1;183(1):283-7 PMID: 8551233
  36. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
    J Exp Med. 1996 Jan 1;183(1):317-22 PMID: 8551239
  37. Antigen processing and presentation by the class I major histocompatibility complex.
    Annu Rev Immunol. 1996;14:369-96 PMID: 8717519
  38. DNA-based immunization by in vivo transfection of dendritic cells.
    Nat Med. 1996 Oct;2(10):1122-8 PMID: 8837611
  39. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood.
    J Immunol Methods. 1996 Sep 27;196(2):121-35 PMID: 8841451
  40. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability.
    J Immunol Methods. 1996 Sep 27;196(2):137-51 PMID: 8841452
  41. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis.
    J Exp Med. 1996 Nov 1;184(5):1791-800 PMID: 8920867
  42. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory.
    J Exp Med. 1996 Nov 1;184(5):1801-13 PMID: 8920868
  43. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes.
    Eur J Immunol. 1996 Nov;26(11):2595-600 PMID: 8921944
  44. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells.
    J Immunol. 1997 Feb 15;158(4):1796-802 PMID: 9029118
  45. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.
    J Immunol. 1997 Mar 15;158(6):2723-30 PMID: 9058806
  46. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL.
    J Immunol. 1997 Apr 1;158(7):3270-6 PMID: 9120283
  47. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    J Immunol. 1997 Apr 1;158(7):3325-34 PMID: 9120290
  48. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.
    Annu Rev Immunol. 1997;15:405-31 PMID: 9143694
  49. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response.
    J Exp Med. 1997 May 5;185(9):1605-17 PMID: 9151898
  50. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
    Cell Immunol. 1997 Jul 10;179(1):84-95 PMID: 9259775
  51. Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro.
    J Immunother. 1998 Mar;21(2):149-57 PMID: 9551367
  52. Dendritic cells efficiently induce protective antiviral immunity.
    J Virol. 1998 May;72(5):3812-8 PMID: 9557664
  53. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo.
    J Exp Med. 1998 May 4;187(9):1395-402 PMID: 9565632
  54. HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex.
    J Immunol. 1998 Nov 15;161(10):5252-9 PMID: 9820497
  55. Mutations in the alpha 2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide.
    J Exp Med. 1988 Aug 1;168(2):725-36 PMID: 3261776
  56. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro.
    J Exp Med. 1989 Apr 1;169(4):1255-64 PMID: 2784483
  57. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals.
    Transplantation. 1990 May;49(5):944-53 PMID: 2159663
  58. Sequence variation of cytotoxic T cell epitopes in different isolates of Epstein-Barr virus.
    Eur J Immunol. 1992 Jan;22(1):183-9 PMID: 1370413
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1999-01-00
Pages
334-42
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC103838
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]